Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia-Reference-Cited by-同舟云学术

Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia

Published:2017-09-11 Issue:3 Volume:44 Page:593-602
ISSN:0586-7614
Container-title:Schizophrenia Bulletin
language:en
Short-container-title:

Author:

Hopkins Seth C¹,Ogirala Ajay¹,Loebel Antony¹,Koblan Kenneth S¹

Affiliation:

1. Sunovion Pharmaceuticals Inc., 84 Waterford Drive, Marlborough, MA

Funder

Sunovion Pharmaceuticals Inc.

Publisher

Oxford University Press (OUP)

Subject

Psychiatry and Mental health

Link

http://academic.oup.com/schizophreniabulletin/article-pdf/44/3/593/24566187/sbx101.pdf

Reference37 articles.

1. The positive and negative syndrome scale (PANSS) for schizophrenia;Kay;Schizophr Bull,1987

2. Five factor model of schizophrenia: replication across samples;Lindenmayer;Schizophr Res,1995

3. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials;Marder;J Clin Psychiatry,1997

4. An exploration of the psychometric properties of the French version of the Positive and Negative Syndrome Scale;Lançon;Can J Psychiatry,1999

5. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia;Wallwork;Schizophr Res,2012

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A clinical trial inclusion criteria to enrich for patients presenting with canonical symptom structure in bipolar depression;Contemporary Clinical Trials;2024-10

2. Epigenetic profile of the immune system associated with symptom severity and treatment response in schizophrenia;Journal of Psychiatry and Neuroscience;2024-02-15

3. The kynurenine pathway in treatment-resistant schizophrenia at the crossroads between pathophysiology and pharmacotherapy;Schizophrenia Research;2024-02

4. OXTR polymorphisms associated with severity and treatment responses of schizophrenia;Schizophrenia;2024-01-06

5. Negative symptoms in schizophrenia: Newly emerging measurements, pathways, and treatments;Schizophrenia Research;2023-08